FDA approval of ketamine spray signals 'major shift' in depression therapy
It is ‘quite likely’ the TGA will approve the drug to treat resistant depression in Australia, says psychiatrist
15th March 2019
By Lydia Hales
The approval by the US Food and Drug Administration of a ketamine-like nasal spray for treatment-resistant depression has been described as a paradigm shift by a leading Australian psychiatrist.